Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the pediatric blood and marrow transplant consortium

Medical and Pediatric Oncology

Volumn 35, Issue 4, 2000, Pages 403-409

  Sandler, E S ^a,f   Hagg, R ^a   Coppes, M J ^b   Mustafa, M M ^a   Gamis, A ^c   Kamani, N ^d   Wall, D ^e  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALBERTA CHILDREN'S HOSPITAL   (Canada)

^c CHILDREN S MERCY HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SAINT LOUIS UNIVERSITY   (United States)

^f NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Busulfan; Cyclophosphamide; Etoposide; Hematopoietic stem cell transplant; Pediatric AML

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGRAFT; ARTICLE; BACTEREMIA; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; SEPSIS; SKIN TOXICITY; TREATMENT OUTCOME; VEIN OCCLUSION;

ADOLESCENT; ALBERTA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MISSOURI; TEXAS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 0033805605     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/1096-911X(20001001)35:4<403::AID-MPO2>3.0.CO;2-M     Document Type: Article

References (40)

1. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group
2. Improved survival for patients with acute myelogenous leukemia
3. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia
4. Allogeneic bone marrow transplantation vs. aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP)
5. Bone marrow transplantation vs chemotherapy in acute non-lymphocytic leukemia: A metaanalytic review. Commentary
6. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. Transplantation vs. intensive chemotherapy in AML. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups
7. Allogeneic or autologous bone marrow transplantation for acute non-lymphocytic leukemia in first remission
8. Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: An update of the Genoa experience with 159 patients
9. Bone marrow transplantation for children with acute myelogenous leukemia
10. Bone marrow transplantation for acute myelogenous leukemia: Recent advances
11. Successful treatment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busulfan/cyclophosphamide and unpurged marrow: The British Autograft Group experience
12. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission
13. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
14. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes
15. Allogeneic bone marrow transplantation following a busulfanbased conditioning regimen in young children with acute lymphoblastic leukemia: A cooperative study of the Societe Francaise de Greffe de Moelle
16. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2
17. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan
18. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: The impact of conditioning regimen without total-body irradiation - A report from the Societe Francaise de Greffe de Moelle
19. Phase I study of busulfan, cyclophosphamide, and timed sequential escalating doses of cytarabine followed by bone marrow transplantation
20. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies
21. Are new conditioning regimens for transplants in acute myelogenous leukemia better?
22. Etoposide in acute non-lymphoblastic leukemia
23. Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation
24. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplant
25. Regimen related toxicity in patients undergoing bone marrow transplantation
26. Clinical manifestation of graft vs. host disease in human recipients of marrow from HLA matched sibling donors
27. Nonparametric estimates from incomplete observations
28. Venoocclusive disease of the liver following bone marrow transplantation
29. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide
30. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen
31. Childhood acute myeloid leukemia: Outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation
32. Improved results of allogeneic BMT using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy
33. Treatment of infant leukemia with busulfan, cyclophosphamide +/etoposide and bone marrow transplantation
34. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics
35. Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukemia
36. Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation
37. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?
38. Prevention of hepatic venoocclusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
39. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation
40. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind placebo-controlled trial